Literature DB >> 2989669

Effective cisplatin (DDP) based chemotherapy in the treatment of hepatoblastoma.

E C Douglass, A A Green, E Wrenn, J Champion, M Shipp, C B Pratt.   

Abstract

Nine of 11 patients with hepatoblastoma treated with cisplatin (DDP) based chemotherapy had a complete (CR) or partial (PR) remission. Five of these patients had measurable pulmonary disease and four achieved a CR of pulmonary lesions. The average interval of disease control following DDP was three times that of Adriamycin (ADR). DDP is an effective agent in the treatment of hepatoblastoma.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2989669     DOI: 10.1002/mpo.2950130405

Source DB:  PubMed          Journal:  Med Pediatr Oncol        ISSN: 0098-1532


  18 in total

Review 1.  [Current status of diagnosis and treatment of hepatoblastoma].

Authors:  Purificación García-Miguel; Manuel López Santamaría
Journal:  Clin Transl Oncol       Date:  2005-08       Impact factor: 3.405

2.  Low-dose methotrexate therapy for hepatoblastoma.

Authors:  S D Weitman; G J Kato; J L Barbosa; B A Kamen
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

Review 3.  A case of hepatoblastoma occurring in an adult.

Authors:  K Sugino; K Dohi; T Matsuyama; T Asahara; M Yamamoto
Journal:  Jpn J Surg       Date:  1989-07

4.  Treatment of unresectable hepatoblastoma with cisplatin, vincristine and 5-fluorouracil.

Authors:  T Herlin; K Norup; K Storm
Journal:  Eur J Pediatr       Date:  1988-06       Impact factor: 3.183

Review 5.  Primary malignant liver tumors in children.

Authors:  Sandeep Agarwala
Journal:  Indian J Pediatr       Date:  2012-03-01       Impact factor: 1.967

6.  Upfront window vincristine/irinotecan treatment of high-risk hepatoblastoma: A report from the Children's Oncology Group AHEP0731 study committee.

Authors:  Howard M Katzenstein; Wayne L Furman; Marcio H Malogolowkin; Mark D Krailo; M Beth McCarville; Alexander J Towbin; Greg M Tiao; Milton J Finegold; Sarangarajan Ranganathan; Stephen P Dunn; Max R Langham; Eugene D McGahren; Carlos Rodriguez-Galindo; Rebecka L Meyers
Journal:  Cancer       Date:  2017-02-17       Impact factor: 6.860

Review 7.  Current and future management strategies for relapsed or progressive hepatoblastoma.

Authors:  Rajkumar Venkatramani; Wayne L Furman; Joerg Fuchs; Steven W Warmann; Marcio H Malogolowkin
Journal:  Paediatr Drugs       Date:  2012-08-01       Impact factor: 3.022

8.  ER stress and ASK1-JNK activation contribute to oridonin-induced apoptosis and growth inhibition in cultured human hepatoblastoma HuH-6 cells.

Authors:  Duo-te Cai; Hua Jin; Qi-Xing Xiong; Wei-Guang Liu; Zhi-gang Gao; Gui-xiong Gu; Yu-hui Qiu
Journal:  Mol Cell Biochem       Date:  2013-04-12       Impact factor: 3.396

9.  Cisplatin therapy in infants: short and long-term morbidity.

Authors:  P R Brock; E C Yeomans; S C Bellman; J Pritchard
Journal:  Br J Cancer Suppl       Date:  1992-08

Review 10.  Rare Tumors in Children: Progress Through Collaboration.

Authors:  Alberto S Pappo; Wayne L Furman; Kris A Schultz; Andrea Ferrari; Lee Helman; Mark D Krailo
Journal:  J Clin Oncol       Date:  2015-08-24       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.